

Scientific programme – overview

Tuesday 28 September

Room ABC

Lunch 12:00–13:10
Opening Ceremony 13:10–13:15
Michel Clavel Lecture 13:15–14:00
Keynote Lecture 14:00–14:45
Coffee Break 14:45–15:15
Plenary Session 1 Applications of proteomics and genomics in drug discovery 15:15–17:20
Welcome Reception 17:30

Wednesday 29 September

Room A	Room B	Room C
Workshop 1 Marketing approval for anticancer agent – the perspective of a worldwide co-ordination! 08:00–9:45	Workshop 2 Preclinical models 08:00–9:45	Workshop 3 Mechanistic combinations 08:00–9:45
Coffee Break 09:45–10:15		
Workshop 4 Practical issues in tissue research 10:15–12:00	Workshop 5 Tumour vaccines 10:15–12:00	Workshop 6 Pharmaceutical industry, investigators and institutions: partners or tools? Practical issues in clinical cancer drug development 08:00–9:45
Lunch/Poster Sessions 12:00–14:40	Poster Sessions New drug targets Drug screening Drug design and synthesis Structure-activity relationships Angiogenesis and metastasis inhibitors Apoptosis	
Keynote Lecture 14:40–15:00		
Plenary Session 2 Proffered papers 15:00–16:00		
Coffee Break 16:00–16:30		
Plenary Session 3 AKT/PTEN/Survival pathways 16:30–18:15		

Thursday 30 September**Room ABC**

Plenary Session 4
Proteasome inhibitors,
antichaperone drugs,
stress pathway inhibitors
08:00–9:45

Coffee Break
09:45–10:15

Plenary Session 5
Hypoxia as a target
10:15–12:00

Lunch/Poster Sessions
12:00–15:00

Plenary Session 6
Proffered papers
15:00–16:00

Coffee Break
16:00–16:30

Plenary Session 7
Chromatin modifying
agents
16:30–18:15

GET-TOGETHER PARTY
20:00

Poster Sessions

Cancer vaccines
Cellular therapies
and cytokines
Monoclonal antibodies
and targeted
toxins/nucleides
Signal transduction
modulators
Cyclins and CDKs
Telomerase-targeting
agents
Gene therapy and
antisense approaches

Friday 1 October**Room ABC**

Plenary Session 8
Optimising targets for
angiogenic inhibition
08:00–9:45

Coffee Break
09:45–10:15

Plenary Session 9
Apoptosis pathway
targeting agents
10:15–12:00

Lunch/Poster Sessions
12:00–14:00

Plenary Session 10
Stroma as a target
14:00–15:45

Closing Ceremony
15:45–15:50

Poster Sessions

Anthracyclines
DNA repair
Antimetabolites
Bioreductive agents
Topoisomerase I inhibitors
Topoisomerase II inhibitors
Tubulin-interacting agents
DNA-interactive agents
Marine compound
Natural products
Prodrugs
Chemoprevention
Clinical methodology
Regulatory affairs
Drug delivery
Drug resistance and modifiers
Radiation interactive agents
Hormonal agents